Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Quinones Stories

2014-01-14 04:21:01

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio. "We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move...

2013-10-21 04:20:56

-- Findings Suggest New Class of Anti-Cancer Agents with Novel Mechanism for Tumor Cell Killing -- SEATTLE, Oct. 21, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the presentation of findings from a preclinical study of PIXUVRI(®) (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin. PIXUVRI is a first-in-class aza-anthracenedione with unique structural...

2013-05-20 04:20:42

- Pricing Negotiations to Begin in June - SEATTLE, May 20, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy. The G-BA reported that additional...

2013-05-02 16:28:43

- Conference call scheduled today at 4:30 p.m. Eastern time - SEATTLE, May 2, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we generated initial commercial sales of PIXUVRI(®) in countries in the European Union where there is market access pending the completion of the reimbursement process," said James Bianco, M.D., President and CEO of CTI....

2013-03-01 20:22:45

SEATTLE, March 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the private German Institute for Quality and Efficiency in Health Care (IQWiG) has published its report on the preliminary benefit assessment of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In May 2012, the European Commission (EC) granted conditional marketing...

2012-12-17 04:21:51

SEATTLE, Dec. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the publication of results from a preclinical study of Pixuvri(TM) (pixantrone) in the The Journal of Pharmacology and Experimental Therapeutics providing potential mechanisms for lower cardiotoxicity in patients treated with Pixuvri who received prior doxorubicin therapy. While CHOP-R is considered an effective therapy and is the standard of care in first line treatment of aggressive...

2012-11-12 20:21:44

BOCA RATON, Fla., Nov. 12, 2012 /PRNewswire/ -- Dr. Steven Joyal from Life Extension, a Fort Lauderdale, Fla-based organization dedicated to the extension of the healthy human lifespan, returns to The SUZANNE Show this week to discuss cellular energy. His appearance, which is one in a series devoted to natural health and longevity, airs Wednesday, November 14, at 7 a.m. (ET/PT) on Lifetime Television. (Logo: http://photos.prnewswire.com/prnh/20121030/FL02749LOGO ) "The energy that...

2012-09-10 22:23:08

SEATTLE, Sept. 11, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union ("E.U.") with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to France,...

2012-06-19 11:10:05

A new study shows that the compound Coenzyme Q10 (CoQ) reduces oxidative damage, a key finding that hints at its potential to slow the progression of Huntington disease. The discovery, which appears in the inaugural issue of the Journal of Huntington's Disease, also points to a new biomarker that could be used to screen experimental treatments for this and other neurological disorders. "This study supports the hypothesis that CoQ exerts antioxidant effects in patients with Huntington's...

2012-05-27 23:02:09

UK´s top bid management company, Executive Compass continues its winning streak as evidenced by the report of impressive seventeen important successes for its clients in its latest newsletter. London, UK (PRWEB) May 26, 2012 Executive Compass continues to rage into the first half of 2012 with one win after another. In March and April alone, the bid management company successfully secured seventeen successes comprised of contract wins and those still in the PQQ stage. The report only...